For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.
New research reveals GPR31’s role in immune response to gut infections
Researchers from Osaka University discover that the GPR31 path in ‘gut surveillance’ cells detects bacterial metabolites and triggers immune responses, opening new possibilities for drug